FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283208488> ?p ?o ?g. }

• W4283208488 endingPage "3695" @default.
• W4283208488 startingPage "3678" @default.
• W4283208488 abstract "Despite currently available treatments for adults with relapsed/refractory acute lymphoblastic leukemia (R/R ALL), survival outcomes remain poor, highlighting the need for new therapeutic strategies. This study estimates the cost-effectiveness of KTE-X19 to treat adults with R/R ALL from a US payer perspective. The model had two components: a decision-tree, where pre-infusion costs for patients who ultimately did not receive KTE-X19 are accounted for, followed by a partitioned survival analysis, where all KTE-X19 infused patients would enter the three-state (pre-progression, progressed disease, death) model. Comparators included current standard of care treatments, i.e., blinatumomab (BLIN), inotuzumab ozogamicin (INO), and salvage chemotherapy (CHEMO). Both standard parametric and mixture cure models were used to model survival. Efficacy, safety, healthcare resource utilization, and health state utility inputs were derived from the ZUMA-3 trial (NCT02614066) and literature. Cost inputs were derived from literature or publicly available sources. Outcomes and costs were discounted 3% annually. Results of KTE-X19 versus comparators are reported as total and incremental life-years (LYs), quality-adjusted life-years (QALYs), costs, and resulting incremental cost-effectiveness ratio (ICER). Deterministic and probabilistic sensitivity analyses (PSA) and key scenario analyses were also performed. In the base case, incremental QALYs for KTE-X19 were 2.44, 3.26, and 4.61 versus BLIN, INO, and CHEMO, respectively. Incremental costs were $50,913, $251,532, and $432,027, respectively, resulting in ICERs of $20,843/QALY (versus BLIN), $77,271/QALY (versus INO), and $93,768/QALY (versus CHEMO). Deterministic sensitivity analysis results were most sensitive to subsequent allogeneic stem cell transplant rates and post-progression utilities. PSA found that KTE-X19 is 78.4%, 74.0%, and 75.4% likely to be cost-effective versus BLIN, INO, and CHEMO, respectively. Across most scenarios, at a willingness-to-pay (WTP) threshold of $150,000/QALY, KTE-X19 was cost-effective versus all treatments. Compared to current options for adults with R/R ALL, KTE-X19 is cost-effective, driven primarily by improved survival. Several treatments for adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (R/R B-ALL) have been approved in the past decade in the US, including blinatumomab (BLIN) and inotuzumab ozogamicin (INO). However, despite the high costs associated with these treatments, survival for patients remains poor. KTE-X19, an autologous anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy, approved by the Food and Drug Administration in October 2021, has potential to improve survival, but its economic value has not yet been determined. This model comprehensively evaluated the long-term clinical and economic value of KTE-X19 versus current treatments, including BLIN, INO, and salvage chemotherapy (CHEMO). Inputs were derived from key clinical trials, the literature, and other publicly available sources. The model used the perspective of a US third party payer over a patient lifetime. Compared to BLIN, INO and CHEMO, KTE-X19 resulted in improved quality of life as measured with incremental quality-adjusted life years (QALYs) of 2.44 (vs BLIN), 3.26 (vs INO), and 4.61 (vs CHEMO). Treatment with KTE-X19 had incremental costs of $50,913 (vs BLIN), $251,532 (vs INO), and $432,027 (vs CHEMO). KTE-X19 was found to provide good value for money based on incremental cost-effectiveness ratios of $20,843/QALY (vs BLIN), $77,271/QALY (vs INO), and $93,768/QALY (vs CHEMO). These values are well below the commonly accepted thresholds to determine economic value. Results were also found to be robust across sensitivity and scenario analyses." @default.
• W4283208488 created "2022-06-22" @default.
• W4283208488 creator A5017205549 @default.
• W4283208488 creator A5025137989 @default.
• W4283208488 creator A5029871910 @default.
• W4283208488 creator A5045200701 @default.
• W4283208488 creator A5050095307 @default.
• W4283208488 creator A5054683366 @default.
• W4283208488 creator A5067710734 @default.
• W4283208488 creator A5081793914 @default.
• W4283208488 creator A5089893290 @default.
• W4283208488 date "2022-06-21" @default.
• W4283208488 modified "2023-10-14" @default.
• W4283208488 title "Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States" @default.
• W4283208488 cites W1701044074 @default.
• W4283208488 cites W1982967337 @default.
• W4283208488 cites W2076003266 @default.
• W4283208488 cites W2078074124 @default.
• W4283208488 cites W2096552494 @default.
• W4283208488 cites W2123974278 @default.
• W4283208488 cites W2164665019 @default.
• W4283208488 cites W2277431766 @default.
• W4283208488 cites W2516611622 @default.
• W4283208488 cites W2591709377 @default.
• W4283208488 cites W2787301955 @default.
• W4283208488 cites W2809572695 @default.
• W4283208488 cites W2884909078 @default.
• W4283208488 cites W2889753173 @default.
• W4283208488 cites W2904009339 @default.
• W4283208488 cites W2904940919 @default.
• W4283208488 cites W2931981435 @default.
• W4283208488 cites W2950219174 @default.
• W4283208488 cites W2999417355 @default.
• W4283208488 cites W3006266640 @default.
• W4283208488 cites W3018120101 @default.
• W4283208488 cites W3033565404 @default.
• W4283208488 cites W3113143481 @default.
• W4283208488 cites W3130692824 @default.
• W4283208488 cites W3169193862 @default.
• W4283208488 cites W3177313466 @default.
• W4283208488 cites W3198687777 @default.
• W4283208488 cites W3211929629 @default.
• W4283208488 cites W3213743659 @default.
• W4283208488 doi "https://doi.org/10.1007/s12325-022-02201-6" @default.
• W4283208488 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35727476" @default.
• W4283208488 hasPublicationYear "2022" @default.
• W4283208488 type Work @default.
• W4283208488 citedByCount "2" @default.
• W4283208488 countsByYear W42832084882023 @default.
• W4283208488 crossrefType "journal-article" @default.
• W4283208488 hasAuthorship W4283208488A5017205549 @default.
• W4283208488 hasAuthorship W4283208488A5025137989 @default.
• W4283208488 hasAuthorship W4283208488A5029871910 @default.
• W4283208488 hasAuthorship W4283208488A5045200701 @default.
• W4283208488 hasAuthorship W4283208488A5050095307 @default.
• W4283208488 hasAuthorship W4283208488A5054683366 @default.
• W4283208488 hasAuthorship W4283208488A5067710734 @default.
• W4283208488 hasAuthorship W4283208488A5081793914 @default.
• W4283208488 hasAuthorship W4283208488A5089893290 @default.
• W4283208488 hasBestOaLocation W42832084881 @default.
• W4283208488 hasConcept C112930515 @default.
• W4283208488 hasConcept C121332964 @default.
• W4283208488 hasConcept C126322002 @default.
• W4283208488 hasConcept C142424586 @default.
• W4283208488 hasConcept C143998085 @default.
• W4283208488 hasConcept C3019080777 @default.
• W4283208488 hasConcept C64332521 @default.
• W4283208488 hasConcept C71924100 @default.
• W4283208488 hasConcept C87355193 @default.
• W4283208488 hasConceptScore W4283208488C112930515 @default.
• W4283208488 hasConceptScore W4283208488C121332964 @default.
• W4283208488 hasConceptScore W4283208488C126322002 @default.
• W4283208488 hasConceptScore W4283208488C142424586 @default.
• W4283208488 hasConceptScore W4283208488C143998085 @default.
• W4283208488 hasConceptScore W4283208488C3019080777 @default.
• W4283208488 hasConceptScore W4283208488C64332521 @default.
• W4283208488 hasConceptScore W4283208488C71924100 @default.
• W4283208488 hasConceptScore W4283208488C87355193 @default.
• W4283208488 hasFunder F4320333647 @default.
• W4283208488 hasIssue "8" @default.
• W4283208488 hasLocation W42832084881 @default.
• W4283208488 hasLocation W42832084882 @default.
• W4283208488 hasLocation W42832084883 @default.
• W4283208488 hasOpenAccess W4283208488 @default.
• W4283208488 hasPrimaryLocation W42832084881 @default.
• W4283208488 hasRelatedWork W2068316626 @default.
• W4283208488 hasRelatedWork W2085089024 @default.
• W4283208488 hasRelatedWork W2110818089 @default.
• W4283208488 hasRelatedWork W2351796763 @default.
• W4283208488 hasRelatedWork W2351985199 @default.
• W4283208488 hasRelatedWork W2403502999 @default.
• W4283208488 hasRelatedWork W2567738959 @default.
• W4283208488 hasRelatedWork W2912565296 @default.
• W4283208488 hasRelatedWork W4297834875 @default.
• W4283208488 hasRelatedWork W4366141624 @default.
• W4283208488 hasVolume "39" @default.
• W4283208488 isParatext "false" @default.
• W4283208488 isRetracted "false" @default.

• next